An Open-label, Comparative Trial of Two Daclizumab Dosing Strategies Versus No Antibody Induction Combined With Tacrolimus (tac), Mycophenolate Mofetil (mmf), and Steroids for the Prevention of Acute Rejection in Simultaneous Kidney/pancreas (skpt) Recipients: Interim Analysis.